Missouri
Provider Communications
Specialty pharmacy prior authorization update - Certain drugs for treatment of ocular conditions continue to require prior authorization
In the March 2021 issue of Provider News, we advised we would no longer require prior authorization for the following drugs used to treat ocular conditions effective May 1, 2021. Please be advised that prior authorization will continue to be required for these drugs. We apologize for any inconvenience.
Drug |
Code |
Code description |
*Avastin |
C9257, J9035 |
intravitreal bevacizumab |
*Mvasi |
Q5107 |
bevacizumab-awwb |
*Zirabev |
Q5118 |
bevacizumab-bvzr |
*Non-oncology use is managed by Anthem’s medical specialty drug review team.
Featured In:
May 2021 Anthem Provider News - Missouri